Co-localization of lymph node therapeutics enhances T cell activation and anti-tumor response

Ruochen Shen1, Senta M Kapnick2, Camilla Edwards1

  • 1Robert E Fischell Institute of Biomedical Devices, University of Maryland College Park, College Park, MD, 20742, United States; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, United States.

Biomaterials
|October 31, 2025
PubMed

Lymph nodes (LNs) are essential tissues in generating and modulating effective immune responses. In this study, we investigated the intra-lymphatic delivery of immunotherapy cues encapsulated in degradable microparticles (MPs). We demonstrate that co-localization of antigens and adjuvants within the same lymph node generates robust antigen-specific T cell responses and significant anti-tumor protection, while spatial separation of cargos across different lymph nodes diminishes immune efficacy. While co-encapsulation of signals in the same particle within a lymph node ensures efficient delivery of both cargos, immune function is equally effectively when particles carrying a single cue are mixed and localized in the same node. This finding demonstrates a strategy for focused, potent responses in lymph nodes using degradable particles that offer attractive translational features, including the flexibility to load individual immunotherapeutic cargos into particles, followed by mixing prior to administration. This feature dramatically simplifies chemistry and manufacturing control (CMC) processes needed for development by avoiding manufacture of candidate immunotherapies that require simultaneous tuning of pharmacokinetic profiles.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.7K